Last reviewed · How we verify
Rescue Medication: Self-Injectable Epinephrine
Epinephrine is a sympathomimetic amine that binds to alpha and beta adrenergic receptors to rapidly reverse the symptoms of anaphylaxis by increasing blood pressure, improving airway patency, and reducing allergic mediator release.
Epinephrine is a sympathomimetic amine that binds to alpha and beta adrenergic receptors to rapidly reverse the symptoms of anaphylaxis by increasing blood pressure, improving airway patency, and reducing allergic mediator release. Used for Anaphylaxis (emergency rescue treatment), Severe allergic reactions.
At a glance
| Generic name | Rescue Medication: Self-Injectable Epinephrine |
|---|---|
| Sponsor | ALK-Abelló A/S |
| Drug class | Sympathomimetic amine; Adrenergic agonist |
| Target | Alpha-1 adrenergic receptor; Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology; Allergy/Anaphylaxis |
| Phase | Phase 3 |
Mechanism of action
Epinephrine acts as a non-selective adrenergic agonist, stimulating alpha-1 receptors to cause vasoconstriction and increase blood pressure, and beta-2 receptors to promote bronchodilation and reduce airway edema. It also stabilizes mast cells and basophils, reducing further release of inflammatory mediators such as histamine and leukotrienes that drive anaphylactic reactions.
Approved indications
- Anaphylaxis (emergency rescue treatment)
- Severe allergic reactions
Common side effects
- Tremor
- Anxiety
- Palpitations
- Headache
- Dizziness
- Hypertension
Key clinical trials
- Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008) (PHASE3)
- Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607) (PHASE3)
- Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: